Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT^® blood-based lung nodule test. Clinical data is one of the foundational pillars driving the success of Biodesix through market adoption and payor coverage of its diagnostic tests.  

Read more at globenewswire.com